NZ532278A - Combination of a PDE inhibitor and an NSAID - Google Patents

Combination of a PDE inhibitor and an NSAID

Info

Publication number
NZ532278A
NZ532278A NZ532278A NZ53227802A NZ532278A NZ 532278 A NZ532278 A NZ 532278A NZ 532278 A NZ532278 A NZ 532278A NZ 53227802 A NZ53227802 A NZ 53227802A NZ 532278 A NZ532278 A NZ 532278A
Authority
NZ
New Zealand
Prior art keywords
inn
active ingredient
pharmaceutically acceptable
acceptable derivatives
acid
Prior art date
Application number
NZ532278A
Other languages
English (en)
Inventor
Thomas Klein
Hans-Peter Kley
Armin Hatzelmann
Manfrid Eltze
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Publication of NZ532278A publication Critical patent/NZ532278A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ532278A 2001-09-19 2002-09-17 Combination of a PDE inhibitor and an NSAID NZ532278A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01000473 2001-09-19
PCT/EP2002/010424 WO2003024489A2 (en) 2001-09-19 2002-09-17 Combination of a nsaid and a pde-4 inhibitor

Publications (1)

Publication Number Publication Date
NZ532278A true NZ532278A (en) 2006-02-24

Family

ID=8176065

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ532278A NZ532278A (en) 2001-09-19 2002-09-17 Combination of a PDE inhibitor and an NSAID

Country Status (25)

Country Link
US (2) US20040242597A1 (pl)
EP (1) EP1429807B1 (pl)
JP (1) JP4588998B2 (pl)
KR (1) KR100949528B1 (pl)
CN (1) CN100496607C (pl)
AT (1) ATE355080T1 (pl)
AU (1) AU2002337105B2 (pl)
BR (1) BR0212606A (pl)
CA (1) CA2459757C (pl)
CY (1) CY1108011T1 (pl)
DE (1) DE60218497T2 (pl)
DK (1) DK1429807T3 (pl)
EA (1) EA008108B1 (pl)
ES (1) ES2282469T3 (pl)
HK (1) HK1066730A1 (pl)
HU (1) HU229442B1 (pl)
IL (2) IL160271A0 (pl)
MX (1) MXPA04002562A (pl)
NO (1) NO331756B1 (pl)
NZ (1) NZ532278A (pl)
PL (1) PL210463B1 (pl)
PT (1) PT1429807E (pl)
SI (1) SI1429807T1 (pl)
WO (1) WO2003024489A2 (pl)
ZA (1) ZA200402654B (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004110424A1 (en) * 2003-05-28 2004-12-23 Glaxo Group Limited Method and pharmaceutical formulation for reducing stress-induced accelerated colonic transit in a mammal
WO2005016334A1 (en) * 2003-08-07 2005-02-24 B.M.R.A. Corporation B.V. Compositions and methods involving the combination of a thromboxane a2 receptor antagonist and an inhibitor of cyclooxigenase-1
EP1691797A2 (en) * 2003-10-21 2006-08-23 Pharmacia Corporation Combination of cyclooxygenase-2 inhibitor and phosphodiesterase 4 inhibitor and method
EP1683521A1 (en) * 2005-01-21 2006-07-26 Centre National De La Recherche Scientifique (Cnrs) Peptide deformylase inhibitors, their use, and pharmaceutical compositions containing the same
EP1688413A1 (en) * 2005-02-03 2006-08-09 Hikma Pharmaceuticals Co. Ltd. Benzoxazole derivatives for the prophylaxis and treatment of inflammatory bowel diseases
CA2600822A1 (en) * 2005-03-14 2006-09-21 Nycomed Gmbh Method for preventing cardiovascular diseases
EP1898894A1 (en) * 2005-06-17 2008-03-19 Boehringer Ingelheim International GmbH Mrp iv inhibitors for the treatment of respiratory diseases
DK2012763T3 (da) * 2006-04-28 2011-05-02 Gruenenthal Gmbh Farmaceutisk kombination omfattende 3-(3-dimethylamono-1-ethyl-2-methyl-propyl) phenol og et NSAID
FR2909876A1 (fr) * 2006-12-19 2008-06-20 Galderma Res & Dev S N C Snc Utilisation du nepafenac ou ses derives pour le traitement de desordres dermatologiques
JP5406215B2 (ja) 2008-01-25 2014-02-05 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー ＴＮＦ−α合成の調節因子及びＰＤＥ４阻害剤としての三環系化合物
US8298536B2 (en) * 2008-03-04 2012-10-30 Pfizer Limited Methods of treating inflammatory pain
CA2753604A1 (en) * 2009-02-27 2010-09-02 Boehringer Ingelheim International Gmbh Drug combinations containing pde4-inhibitors and nsaids
EP2400961B1 (de) 2009-02-27 2017-11-22 Boehringer Ingelheim International GmbH Arzneimittelkombinationen enthaltend pde4-inhibitoren und nsaids
CN105121439A (zh) 2013-02-19 2015-12-02 辉瑞公司 作为pde4亚型抑制剂用于治疗cns和其他病症的氮杂苯并咪唑化合物
EP3172210B1 (en) 2014-07-24 2020-01-15 Pfizer Inc Pyrazolopyrimidine compounds
KR102061952B1 (ko) 2014-08-06 2020-01-02 화이자 인코포레이티드 이미다조피리다진 화합물
WO2019147824A1 (en) 2018-01-26 2019-08-01 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
WO2020106754A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
EP4069213A1 (en) * 2019-12-03 2022-10-12 The USA, as represented by The Secretary, Department of Health and Human Services Cyclooxygenase-2 inhibition for the treatment of saa-high asthma
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
US20230090417A1 (en) * 2021-09-22 2023-03-23 Iolyx Therapeutics, Inc. Methods of treating ocular inflammatory diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1229075B (it) * 1985-04-05 1991-07-17 Fidia Farmaceutici Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico
GB2228736A (en) 1989-02-10 1990-09-05 Sterivet Lab Ltd Cosmetic formulation
ES2137113B1 (es) * 1997-07-29 2000-09-16 Almirall Prodesfarma Sa Nuevos derivados de triazolo-piridazinas heterociclicos.
ID23921A (id) 1997-11-04 2000-05-25 Pfizer Prod Inc Penggantian indazola bioisostere katekol pada senyawa-senyawa aktif untuk terapi
NZ515711A (en) 1999-06-24 2004-01-30 Pharmacia Corp Combination of tumors necrocis factor (TNF) antagonists and COX-2 inhibitors for the treatment of inflammation
EP2193808A1 (en) * 1999-08-21 2010-06-09 Nycomed GmbH Synergistic combination
US6174878B1 (en) * 1999-08-31 2001-01-16 Alcon Laboratories, Inc. Topical use of kappa opioid agonists to treat otic pain
ECSP003747A (es) * 1999-11-02 2002-05-23 Smithkline Beecham Corp Metodo y composiciones para el tratamiento de las enfermedades pulmonares
US6410563B1 (en) * 1999-12-22 2002-06-25 Merck Frosst Canada & Co. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
US6372777B1 (en) * 1999-12-23 2002-04-16 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
KR20020072299A (ko) * 2000-01-31 2002-09-14 화이자 프로덕츠 인코포레이티드 Ｐｄｅ4 이소자임의 선택적 억제제로서 유용한니코틴아미드 벤조접합된-헤테로사이클릴 유도체
JP2003522142A (ja) * 2000-02-08 2003-07-22 スミスクライン・ビーチャム・コーポレイション 炎症性疾患の治療法および治療用組成物
PL364910A1 (pl) * 2001-01-31 2004-12-27 Pfizer Products Inc. Pochodne eterów użyteczne jako inhibitory izoenzymów PDE4
EE05386B1 (et) * 2001-02-15 2011-02-15 ALTANA�Pharma�AG Ftalasinoon-piperidinoderivaadid,ÁnendeÁkasutamineÁjaÁravim

Also Published As

Publication number Publication date
US20080255209A1 (en) 2008-10-16
EP1429807B1 (en) 2007-02-28
EP1429807A2 (en) 2004-06-23
JP2005504077A (ja) 2005-02-10
CA2459757A1 (en) 2003-03-27
KR100949528B1 (ko) 2010-03-25
HK1066730A1 (en) 2005-04-01
CA2459757C (en) 2011-08-30
HU229442B1 (hu) 2013-12-30
DE60218497T2 (de) 2007-11-08
PT1429807E (pt) 2007-05-31
IL160271A (en) 2008-03-20
MXPA04002562A (es) 2004-05-31
EA008108B1 (ru) 2007-04-27
DK1429807T3 (da) 2007-06-18
ZA200402654B (en) 2005-04-26
IL160271A0 (en) 2004-07-25
US8242146B2 (en) 2012-08-14
HUP0401582A3 (en) 2008-04-28
US20040242597A1 (en) 2004-12-02
AU2002337105B2 (en) 2008-03-20
ATE355080T1 (de) 2006-03-15
CY1108011T1 (el) 2013-09-04
WO2003024489A3 (en) 2003-09-18
PL369472A1 (pl) 2005-04-18
KR20040053129A (ko) 2004-06-23
HUP0401582A2 (hu) 2004-11-29
CN1625411A (zh) 2005-06-08
NO331756B1 (no) 2012-03-19
BR0212606A (pt) 2004-08-17
JP4588998B2 (ja) 2010-12-01
DE60218497D1 (de) 2007-04-12
EA200400410A1 (ru) 2004-12-30
CN100496607C (zh) 2009-06-10
WO2003024489A2 (en) 2003-03-27
SI1429807T1 (sl) 2007-08-31
NO20041596L (no) 2004-06-18
ES2282469T3 (es) 2007-10-16
PL210463B1 (pl) 2012-01-31

Similar Documents

Publication Publication Date Title
EP1429807B1 (en) Combination of a nsaid and a pde-4 inhibitor
AU2002337105A1 (en) Combination of a NSAID and a PDE-4 inhibitor
BRPI0620234A2 (pt) combinação farmacêutica para o tratamento de luts que compreende um inibidor da pde5 e um antagonista muscarìnico
EP3194395A1 (en) Sgc stimulators
JP7016853B2 (ja) ｓＧＣ刺激剤のリンプロドラッグ
JPS6143117A (ja) ピリミド‐ピリミジンおよびｏ‐アセチルサリチル酸からなる組合せ生成物
ZA200405379B (en) Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin.
Sorbera et al. Lumiracoxib
EP1429843A2 (en) Combination of a pde inhibitor and a leukotriene receptor antagonist
WO2009109525A1 (en) Use of a specific pde4 inhibitor for the treatment and/or prophylaxis of non-alcoholic fatty liver disease
EP1505985A1 (en) Combination therapy for treating cyclooxygenase-2 mediated diseases in patients at risk of thrombotic cardiovascular events
EP2680838A1 (en) TREATMENT OF ARTERIAL AGEING BY COMBINATION OF RAAS INHIBITOR AND HMG-CoA REDUCTASE INHIBITOR
WO2002083136A1 (en) Therapeutic compositions comprising amino sulfonic acids and their uses
RU2430728C1 (ru) Комбинированное антиагрегантное и антиоксидантное лекарственное средство
NO329495B1 (no) Galeniske former for oral administrasjon med forlenget frigjoring av molsidomin
US20150342989A1 (en) Compositions comprising non steroidal anti-inflammatory drugs and methods of use thereof
EP0971714B1 (en) Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of dementia
WO2023146846A1 (en) Use of non-steroidal anti-inflammatory compounds for treatment of inflammation
Benhalima et al. Niacin, an old drug with new perspectives for the management of dyslipidaemia
AU2013203094B2 (en) Combination of HMG-CoA reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases
CZ2002383A3 (cs) Farmaceutický prostředek k ošetření akutních bolestí
AU2002333851A1 (en) Combination of a PDE inhibitor and a leukotriene receptor antagonist
WO2005117853A1 (ja) 高脂血症治療剤及び糖尿病治療剤

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
ASS Change of ownership

Owner name: NYCOMED GMBH, DE

Free format text: OLD OWNER(S): ALTANA PHARMA AG

RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
ASS Change of ownership

Owner name: TAKEDA GMBH, DE

Effective date: 20150305

LAPS Patent lapsed